Fieldpoint Private Securities’s BioMarin Pharmaceuticals BMRN Stock Holding History

Fieldpoint Private Securities’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$96K	Sell	1,155 -3	-0.3%	-$239	0.03%	374
2022 Q1	$89K	Buy	+1,158	New	+$96.9K	0.02%	453
2021 Q3	–	Sell	-1,627	Closed	-$125K	–	1644
2021 Q2	$125K	Sell	1,627 -268	-14%	-$21.2K	0.03%	377
2021 Q1	$143K	Sell	1,895 -527	-22%	-$43K	0.03%	339
2020 Q4	$212K	Sell	2,422 -369	-13%	-$29.3K	0.05%	276
2020 Q3	$212K	Buy	2,791 +716	+35%	+$72.4K	0.06%	261
2020 Q2	$256K	Sell	2,075 -2,885	-58%	-$287K	0.09%	206
2020 Q1	$419K	Buy	4,960 +232	+5%	+$20K	0.16%	147
2019 Q4	$400K	Buy	4,728 +1,435	+44%	+$108K	0.12%	179
2019 Q3	$222K	Buy	3,293 +900	+38%	+$69.3K	0.08%	205
2019 Q2	$205K	Sell	2,393 -305	-11%	-$26.1K	0.06%	226
2019 Q1	$240K	Sell	2,698 -280	-9%	-$26K	0.1%	181
2018 Q4	$254K	Buy	+2,978	New	+$283K	0.11%	171

Other funds holding BMRN

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Fieldpoint Private Securities's BMRN Position: Q2 2022 in Review

Fieldpoint Private Securities reduced its BioMarin Pharmaceuticals (BMRN) stake by 0.26% in Q2 2022, selling an estimated $239 and leaving 1,155 shares worth $96K. The position accounts for 0.03% of the portfolio, ranked #374.

Fieldpoint Private Securities first reported a position in BMRN in Q4 2018 and has held it in 13 quarters since. The position peaked at $419K in Q1 2020. 543 funds tracked by Wall St. Rank hold BMRN as of Q2 2022.

Fieldpoint Private Securities held 1,155 shares of BioMarin Pharmaceuticals worth $96K as of Q2 2022.
Fieldpoint Private Securities sold 3 BioMarin Pharmaceuticals shares in Q2 2022, an estimated $239.
BioMarin Pharmaceuticals made up 0.03% of Fieldpoint Private Securities's portfolio in Q2 2022, its #374 holding.
Fieldpoint Private Securities first reported a position in BioMarin Pharmaceuticals in Q4 2018 and has held it in 13 quarters since.
Fieldpoint Private Securities's BioMarin Pharmaceuticals position peaked at $419K in Q1 2020.
543 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2022.

Based on Fieldpoint Private Securities's 13F filing for Q2 2022, filed 5 Aug 2022.